Depression

Every compound in the sci-wiki that affects depression; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

1 sourced · 1 reference

←depression2/2

Nootropic

Nemifitide

Nemifitide (originally coded INN 00835, and briefly called netamiftide) is a synthetic pentapeptide that was developed as an injectable antidepressant. Its sequence is 4-fluoro-L-phenylalanyl-trans-4-hydroxy-L-prolyl-L-arginyl-glycyl-L-tryptophanamide, and it is a structural analog of MIF-1 (melanocyte-inhibiting factor-1, the tripeptide Pro-Leu-Gly-NH2). It was studied by Innapharma, later Tetragenex Pharmaceuticals, and reached Phase II trials in major depressive disorder before development stalled; it was never approved. The interesting thing about it is the mismatch between its pharmacokinetics and its effect: the peptide clears the blood in well under an hour, yet the antidepressant response reported in trials came on within days and lasted weeks to months after a short dosing course. It was given as a subcutaneous injection, not a pill, and its tolerability was consistently good with side effects limited mostly to the injection site.

1 outlet

reference shelf; no outlet carries these yet

Antidepressant

Itruvone

Itruvone (development code PH-10, also written PH10) is an investigational synthetic neuroactive steroid of the pherine class being studied as a rapid-acting intranasal treatment for major depressive disorder. Chemically a pregnane steroid (pregn-4-en-20-yn-3-one, an ethynyl-substituted steroid backbone), it is delivered as a low-dose aqueous nasal spray and is proposed to act through a novel chemosensory mechanism, engaging receptors in the nasal lining that signal to limbic (emotion-processing) brain circuits without meaningful systemic absorption. In an early exploratory randomized trial it separated from placebo on standard depression rating scales within the first week of treatment and showed a benign side-effect profile, though its evidence base remains limited to small studies. It is developed by Vistagen and is frequently confused with its sibling pherine fasedienol (PH94B), which targets social anxiety disorder instead.

reference